- Home
- BCRX vs PHVS Comparison
BCRX vs PHVS Comparison
Compare BCRX & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCRX
- PHVS
- Stock Information
- Founded
- BCRX 1986
- PHVS 2015
- Country
- BCRX United States
- PHVS Switzerland
- Employees
- BCRX N/A
- PHVS N/A
- Industry
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- BCRX Health Care
- PHVS Health Care
- Exchange
- BCRX Nasdaq
- PHVS Nasdaq
- Market Cap
- BCRX 1.8B
- PHVS 1.6B
- IPO Year
- BCRX 1994
- PHVS 2021
- Fundamental
- Price
- BCRX $7.28
- PHVS $22.96
- Analyst Decision
- BCRX Strong Buy
- PHVS Buy
- Analyst Count
- BCRX 10
- PHVS 4
- Target Price
- BCRX $16.70
- PHVS $33.00
- AVG Volume (30 Days)
- BCRX 3.1M
- PHVS 225.2K
- Earning Date
- BCRX 11-03-2025
- PHVS 11-12-2025
- Dividend Yield
- BCRX N/A
- PHVS N/A
- EPS Growth
- BCRX N/A
- PHVS N/A
- EPS
- BCRX N/A
- PHVS N/A
- Revenue
- BCRX $557,506,000.00
- PHVS N/A
- Revenue This Year
- BCRX $41.40
- PHVS N/A
- Revenue Next Year
- BCRX $5.33
- PHVS N/A
- P/E Ratio
- BCRX N/A
- PHVS N/A
- Revenue Growth
- BCRX 45.85
- PHVS N/A
- 52 Week Low
- BCRX $6.02
- PHVS $11.51
- 52 Week High
- BCRX $11.31
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- BCRX 38.42
- PHVS 46.27
- Support Level
- BCRX $7.24
- PHVS $22.07
- Resistance Level
- BCRX $7.47
- PHVS $24.01
- Average True Range (ATR)
- BCRX 0.20
- PHVS 1.18
- MACD
- BCRX -0.02
- PHVS -0.28
- Stochastic Oscillator
- BCRX 34.85
- PHVS 22.41
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.